Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities
- PMID: 30129511
- DOI: 10.1016/j.jnma.2017.12.004
Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities
Abstract
Purpose: The purpose of this review is to describe the demographics (age, gender, race and iris color) of subjects enrolled in clinical trials supportive of approved New Molecular Entities (NMEs) in ophthalmology over the last 10 years (2006-2016).
Methods: Publicly available data on Drugs@FDA were reviewed for all 9 approved NMEs, including biologics, from 2006 to 2016.
Results: All NMEs have publicly available data on the race, gender and age of clinical trial participants. Women and white subjects comprise a majority of clinical trial participants (68% and 92%, respectively). FDA analyses on all 9 NMEs did not find any differences across age, gender, race, or iris color subgroups.
Keywords: Clinical trials; Gender; Ophthalmology; Race.
Copyright © 2017 National Medical Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.J Womens Health (Larchmt). 2009 Mar;18(3):303-10. doi: 10.1089/jwh.2008.0971. J Womens Health (Larchmt). 2009. PMID: 19243271
-
Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.Clin Pharmacol Ther. 2018 Nov;104(5):940-948. doi: 10.1002/cpt.1180. Epub 2018 Sep 14. Clin Pharmacol Ther. 2018. PMID: 30218447 Free PMC article.
-
Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.Trials. 2016 Apr 14;17:199. doi: 10.1186/s13063-016-1322-4. Trials. 2016. PMID: 27079511 Free PMC article.
-
Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S. J Natl Med Assoc. 2001. PMID: 11798060 Free PMC article. Review.
-
Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.BMJ Open. 2015 Nov 12;5(11):e009758. doi: 10.1136/bmjopen-2015-009758. BMJ Open. 2015. PMID: 26563214 Free PMC article. Review.
Cited by
-
Representation of Race and Ethnicity in Randomized Clinical Trials of Diabetic Macular Edema and Retinal Vein Occlusion Compared to 2010 US Census Data.JAMA Ophthalmol. 2022 Nov 1;140(11):1096-1102. doi: 10.1001/jamaophthalmol.2022.3929. JAMA Ophthalmol. 2022. PMID: 36201192 Free PMC article.
-
Racial, Ethnic, and Gender Diversity in United States Ophthalmology Clinical Trials.Ophthalmol Sci. 2023 Sep 27;4(1):100402. doi: 10.1016/j.xops.2023.100402. eCollection 2024 Jan-Feb. Ophthalmol Sci. 2023. PMID: 38027420 Free PMC article.
-
Enrolment characteristics in age-related macular degeneration clinical trials: a cross-sectional study.Eye (Lond). 2025 Apr;39(6):1153-1159. doi: 10.1038/s41433-024-03572-6. Epub 2024 Dec 27. Eye (Lond). 2025. PMID: 39730975
-
Sex or Gender Reporting in Ophthalmology Clinical Trials Among US Food and Drug Administration Approvals, 1995 to 2022.JAMA Ophthalmol. 2024 Feb 1;142(2):123-130. doi: 10.1001/jamaophthalmol.2023.6088. JAMA Ophthalmol. 2024. PMID: 38236588 Free PMC article.
-
Representational disparity of sex, race, and ethnicity in presbyopia clinical trials: a cross-sectional study.Eye (Lond). 2023 Dec;37(18):3871-3873. doi: 10.1038/s41433-023-02621-w. Epub 2023 Jul 12. Eye (Lond). 2023. PMID: 37438570 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical